Protalix BioTherapeutics, Inc.
PLX NYSE· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$2.55
KIRA · Stoqly’s AI analyst, in plain words
- Protalix BioTherapeutics, Inc. had $52.7M of revenue in fiscal 2025, down 1.2% on the year before. Over five years, revenue changed −3.5% a year on average.
- Its operating margin was −10.4%, down 17.8 pts: of every 100 in sales, about −10 is left after running the business.
- Protalix BioTherapeutics, Inc. lost $6.6M in fiscal 2025.
- Free cash flow was −$13.6M in fiscal 2025, −25.8% of revenue.
Market cap
$211M
P/E
10.6x
Revenue
$52.7M
Net income
−$6.6M
Free cash flow
−$13.6M
Operating margin
−10.4%
Protalix BioTherapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−1.2%
No. Sales fell 1.2% last year.
Does it make a profit?
−12.5%
No. It lost money last year.
Does profit turn into cash?
−25.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
10.6x
One share costs 10.6 times its yearly profit per share.
What Protalix BioTherapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- Protalix BioTherapeutics, Inc.
- CIK
- 0001006281
Protalix BioTherapeutics, Inc. · PLX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $38.4M | $47.6M | $65.5M | $53.4M | $52.7M |
| Revenue growth | −39.0% | 24.2% | 37.5% | −18.5% | −1.2% |
| Gross margin | 57.4% | 58.9% | 64.9% | 54.5% | 48.8% |
| Operating margin | −53.4% | −27.3% | 16.0% | 7.3% | −10.4% |
| Net income | −$27.6M | −$14.9M | $8.3M | $2.9M | −$6.6M |
| Net margin | −71.9% | −31.3% | 12.7% | 5.5% | −12.5% |
| Diluted EPS | −$0.62 | −$0.31 | $0.09 | $0.04 | −$0.08 |
| Cash | |||||
| Cash from operations | −$10.3M | −$25.0M | −$1.3M | $8.7M | −$12.0M |
| Capital expenditure | $1.5M | $0.6M | $1.1M | $1.3M | $1.6M |
| Free cash flow | −$11.7M | −$25.6M | −$2.5M | $7.4M | −$13.6M |
| FCF margin | −30.6% | −53.8% | −3.8% | 13.8% | −25.8% |
| Share count change | 51.4% | 9.8% | 70.0% | −1.7% | −3.1% |
| Debt and strength | |||||
| Cash and short-term investments | $39.0M | $17.1M | $23.6M | $19.8M | $14.7M |
| Shareholders' equity | −$6.0M | −$10.6M | $33.6M | $43.2M | $48.2M |
| Current ratio | 1.9x | 1.4x | 1.5x | 2.3x | 2.5x |
| Returns and quality | |||||
| Return on equity | — | — | 72.5% | 7.6% | −14.4% |
| Return on tangible equity | — | — | 24.8% | 6.8% | −13.7% |
| Piotroski F-score | 2 | 3 | 4 | 5 | 2 |
| Altman Z'' | −16.0 | −23.1 | −11.3 | −11.9 | −11.0 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Protalix BioTherapeutics, Inc. · PLX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.55 a share, the company is worth $211M: 10.6 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001006281). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.